Compare FMS & AFRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FMS | AFRM |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2B | 14.3B |
| IPO Year | N/A | 2020 |
| Metric | FMS | AFRM |
|---|---|---|
| Price | $23.17 | $66.99 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 25 |
| Target Price | $30.00 | ★ $85.00 |
| AVG Volume (30 Days) | 436.8K | ★ 4.7M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | N/A | ★ 108.98 |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $3,224,412,000.00 |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | $3.83 | $23.95 |
| P/E Ratio | ★ $15.62 | $107.38 |
| Revenue Growth | N/A | ★ 38.80 |
| 52 Week Low | $20.96 | $41.59 |
| 52 Week High | $30.46 | $100.00 |
| Indicator | FMS | AFRM |
|---|---|---|
| Relative Strength Index (RSI) | 52.96 | 78.84 |
| Support Level | $22.50 | $66.87 |
| Resistance Level | $23.36 | $71.66 |
| Average True Range (ATR) | 0.38 | 2.93 |
| MACD | 0.06 | 2.43 |
| Stochastic Oscillator | 64.29 | 99.54 |
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
Founded in 2012, Affirm is a market leader in the buy-now, pay-later space with around $36 billion in transaction volume in fiscal 2025. Affirm offers both zero-interest financing, which is merchant subsidized, and interest-bearing loans, which function as personal loans that are approved on a per-transaction basis. Over 70% of Affirm's transaction volume comes from its interest-bearing loans, which also comprise the majority of its revenue. Affirm operates in the United States, which accounted for more than 95% of its revenue in 2025, but the firm has also expanded to Canada and the United Kingdom.